Table 1 Demographic and clinical characteristics of patients initiating palbociclib + letrozole

Age (years)

At advanced breast cancer diagnosis (mean (SD))

61

(12)

At initiation of palbociclib (mean (SD))

64

(12)

 <65 (n (%))

304

(49.7)

 65–74 (n (%))

182

(29.7)

  ≥75 (n (%))

126

(20.6)

Weight (lbs) at initiation of palbociclib (mean (SD))

165

(37)

BMI (mean (SD))

28.2

(7.6)

Histology (n (%))

 Invasive ductal

190

(31.0)

 Invasive lobular

7

(3.7)

 Unknown

415

(67.8)

Stage recorded in EMR^a (n (%))

 Recurrent

198

(38.4)

 De novo stage IV

278

(45.4)

 Unknown

99

(16.2)

ECOG at palbociclib treatment initiation (n (%))

 0/1

348

(56.9)

 2

77

(12.6)

  ≥3

18

(2.9)

Unknown

169

(27.6)

ER+/HER2 -

 Yes

428

(69.9)

 Unknown

184

(30.1)

ER status (n (%))

 Positive

505

(82.5)

 Negative

33

(5.4)

 Unknown

74

(12.1)

PR status (n (%))

 Positive

388

(63.4)

 Negative

123

(20.1)

 Unknown

101

(16.5)

HER2 status (n (%))

 Positive

38

(6.2)

 Negative

465

(76.0)

 Unknown

109

(17.8)